Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.

Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2023 Dec; 114(12):4643-4653.

View in: PubMed

subject areas

Adult
Antineoplastic Agents
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
Japan
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Non-Hodgkin
Multicenter Studies as Topic

authors with profiles

Yuko Mishima